Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

ACT training reduced burnout in oncology nurses in Iran study

A six-session ACT program lowered burnout and musculoskeletal discomfort in 40 oncology nurses, with the strongest gains in work and patient-related strain.

By Dr. Revathy Mohan V.R., MBBS · Oct 23, 2026 · 5 min read

Oncology·JCI

STING agonism drives osteosarcoma necrosis before T cell regression

Single-cell analysis shows STING agonism rapidly remodels osteosarcoma tumors, triggering myeloid necrosis before later T cell-dependent regression.

Oct 23, 2026

Oncology·STAT

Fibrolamellar hepatocellular carcinoma offers lessons for rare cancer research

A decade of work on fibrolamellar hepatocellular carcinoma clarifies its biology, diagnostic barriers, and the research gaps that…

Oct 23, 2026

Oncology·Becker H

Melanoma Persister Cells Show Plasticity, Signaling Shifts and Metabolic Rewiring

A review in Communications Biology examines melanoma persister cells, their plasticity, rewired signaling, metabolic adaptation, and treatment vulnerabilities.

Oct 23, 2026

Oncology·JCI

PTHrP Drives Breast Cancer Bone Metastases Through Gut Microbiota-Linked T Cells

Mouse data link segmented filamentous bacteria to faster breast cancer bone metastases through PTHrP, Th17/TNF T cells, and…

Oct 23, 2026

Oncology·STAT

Colorectal Cancer Signaling Pathways Shape Targeted Therapy Strategies

A 2024 review examines how signaling pathways drive colorectal cancer and how targeted, immune, and AI-guided therapies may…

Oct 23, 2026

Oncology·ACC-PRO

Neoadjuvant Daromun Improves Recurrence-Free Survival in Stage III Melanoma

Updated phase III PIVOTAL data show neoadjuvant daromun improved recurrence-free and distant metastasis-free survival in resectable stage III…

Oct 23, 2026

Oncology·Nature

Cisplatin Liver Injury Tracks with Platinum Retention and GSH Defense

Male mice showed striking variability in cisplatin liver injury, linked to hepatic platinum retention and glutathione-based defense pathways.

Oct 23, 2026

Oncology·ACC-PRO

Menarini’s Stemline lands Georgiamune preclinical cancer immunotherapy in $1.1B deal

Menarini’s Stemline secured worldwide rights to Georgiamune’s preclinical GIM-621 in a deal worth up to $1.1 billion, led…

Oct 23, 2026

Oncology·Becker H

iConquerFear falls short for ovarian cancer recurrence fear in pilot trial

A pilot trial found limited engagement, mixed acceptability, and distress-related withdrawals with iConquerFear for ovarian cancer survivors.

Oct 23, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.